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This session discussed two targets for therapeutics, onevery new, EML4/anaplastic lymphoma kinase (ALK)
translocation and the other very old, the ras pathway. The
developments in epidermal growth factor receptor (EGFR) in-
hibition have brought these two areas together as disease char-
acterized by these abnormalities is unresponsive to EGFR inhi-
bition. The recent discovery of the EML4/ALK translocation has
identified the underlying biology for another group of patients
characterized by never smoking history and provided a new
target for therapy. Ras mutations and other abnormalities of this
pathway are an old target that has been associated with relative
resistance to EGFR tyrosine kinase inhibitors and conventional
chemotherapeutics.
SUMMARY OF PRESENTATIONS
EML4-ALK and PF 02341066
Drs. Alice Shaw and Ross Camidge presented updates
on EML4/ALK and its inhibitor, PF-02341066 (crizotinib).
Perhaps the most important development this year in oncol-
ogy is the emerging story of the EML4-ALK translocation in
non-small cell lung cancer (NSCLC). This translocation was
originally discovered as part of a rational search by Soda et
al.1 In this seminal article, Soda et al. described the identifi-
cation of the translocation, its transforming nature, the po-
tential of specifically targeted agents to inhibit the fusion
gene with resulting tumor shrinkage in an animal model, and
the demographics of patients who had the gene. These pa-
tients were characterized by a nonsmoking history, adenocar-
cinoma histology, and absence of EGFR mutation.
Shortly after the discovery, the group at Massachusetts
General Hospital began to screen never smoking patients who
were EGFR negative for the translocation. The technique used
was fluorescence in situ hybridization. They identified a number
of patients. They confirmed the findings of Soda et al. that the
phenotype of the patient with EML4/ALK translocation is a
scant or never smoker, relatively young, with an adenocarci-
noma histology, and who is relatively unresponsive to chemo-
therapy or EGFR inhibitors.2 Recently noted is that the patients
seem to have a histologically distinct disease, characterized by a
signet ring-type mucinous adenocarcinoma.3
A fortuitous development was that PF-02341066, which
was already in development as a c-met inhibitor and undergoing
evaluation in patients resistant to EGFR tyrosine kinase inhibi-
tors, also demonstrated significant in vitro activity against cell
lines with activated ALK with an IC50 of 20 nM. During phase
I testing, a patient with the translocation had a significant clinical
response. The ultimate maximum tolerated dose/recommended
phase 2 dose was 250 mg twice daily. The major toxicities
identified were ALT elevation and mild (grades 1 and 2) nausea,
vomiting, fatigue, and “sight disturbance.” Only the ALT ele-
vations were potentially dose limiting.
This phase I trial coupled with the clinical and laboratory
data led to rational testing of the agent in a population of patients
enriched for the EML4/ALK translocation and reported by Dr.
Camidge. Remarkably, there was a response rate of 64% and a
clinical benefit rate (stable disease  partial response  com-
plete response) of 95%. Importantly, much of this benefit was
sustained with a median duration of 19 weeks and a progres-
sion-free survival that was not reached. This result has led to a
phase III trial currently enrolling patients (Figure 1). A phase II
trial is also open for patients with the translocation not meeting
the eligibility requirements for the phase III study.
Ras Targeting
Abnormalities of the ras pathway (Figure 2) are fre-
quent in NSCLC. Activated k-ras is a common abnormality in
NSCLC, particularly in adenocarcinoma. K-ras mutations
are, for the most part, mutually exclusive with EGFR muta-
tions and EML-4/ALK translocations. Dr. Scaglioni pre-
sented a novel approach to targeting this common abnormal-
ity. Downstream effectors of ras activation are mTOR and
phosphatidylinositol 3-kinase. BEZ235 is a dual inhibitor of
phosphatidylinositol 3-kinase and mTOR that is entering
investigation.4 In preclinical models, it has been demon-
strated to suppress tumor growth without causing apoptosis.5
B-RAF
B-raf mutations are relatively uncommon in NSCLC
(2%); however, the advent of an effective agent raises the
possibility that effective treatment for these patients may be
available in the near future. As discussed by Dr. George
Riely, PLX4032 has demonstrated clear evidence of activity
in patients with B-raf mutated melanoma with a response rate
of 70% (albeit with an n  27).6 This agent is currently in an
expansion phase at 960 mg/m2 orally twice daily in B-RAF-
mutated melanoma. The toxicities of the agent are primarily
cutaneous, with rash (68%) and photosensitivity common, but
not usually severe (i.e., grades 1 and 2). Interestingly, a high
incidence of cutaneous squamous cell carcinomas has been
noted. Other toxicities include nausea, fatigue, and LFT
abnormalities. Another potential therapeutic for these patients
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is an inhibitor of MEK, which is downstream of B-RAF with
AZD6244. A trial of this agent is currently in progress.
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FIGURE 1. Profile-1007: Phase 3
study of PF-02341066 vs. pem-
etrexed or docetaxel in patients
with non-small cell lung cancer
(NSCLC) with a translocation or
inversion event involving the ALK
gene locus.
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